166 related articles for article (PubMed ID: 25449685)
1. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
Breccia M; Molica M; Alimena G
Leuk Res; 2014 Dec; 38(12):1392-8. PubMed ID: 25449685
[TBL] [Abstract][Full Text] [Related]
2. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
Lipton JH; Bryden P; Sidhu MK; Huang H; McGarry LJ; Lustgarten S; Mealing S; Woods B; Whelan J; Hawkins N
Leuk Res; 2015 Jan; 39(1):58-64. PubMed ID: 25466286
[TBL] [Abstract][Full Text] [Related]
4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
5. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
8. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Giles FJ; O'Dwyer M; Swords R
Leukemia; 2009 Oct; 23(10):1698-707. PubMed ID: 19474800
[TBL] [Abstract][Full Text] [Related]
9. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia.
Balabanov S; Braig M; Brümmendorf TH
Drug Discov Today Technol; 2014 Mar; 11():89-99. PubMed ID: 24847658
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
11. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
12. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
Samis J; Lee P; Zimmerman D; Arceci RJ; Suttorp M; Hijiya N
Pediatr Blood Cancer; 2016 Aug; 63(8):1332-8. PubMed ID: 27100618
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
14. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
15. Update on emerging treatments for chronic myeloid leukemia.
Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
[TBL] [Abstract][Full Text] [Related]
16. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
Matsumura I
Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Caldemeyer L; Dugan M; Edwards J; Akard L
Curr Hematol Malig Rep; 2016 Apr; 11(2):71-9. PubMed ID: 26922746
[TBL] [Abstract][Full Text] [Related]
18. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
19. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Breccia M; Alimena G
Leuk Res; 2013 Jun; 37(6):713-20. PubMed ID: 23473918
[TBL] [Abstract][Full Text] [Related]
20. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
